Evidence map›Paper›PMID 37766235›Full record

Trial reportViruses2023

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts.

Ilya V Gordeychuk, Liubov I Kozlovskaya, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina and 29 more

Open access · goldAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Promising Vaccine Formulations for Emerging Infectious Diseases.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 5 institutions in 1 country.

Ilya V GordeychukChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0002-4551-7535
Liubov I KozlovskayaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Aleksandra A SiniuginaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Nadezhda V YagovkinaKirov State Medical University of the Ministry of Health of Russia, 610998 Kirov, Russia.
Vladimir I KuzubovHealthcare Unit No. 163 of Federal Medical Biological Agency of Russia, 630559 Novosibirsk Region, Russia.
Konstantin A ZakharovEco-Safety Scientific Research Center, 196143 Saint-Petersburg, Russia.ORCID 0000-0002-0557-0382
Viktor P VolokChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Maria S DodinaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Larissa V GmylChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Natalya A KorotinaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Rostislav D TheodorovichChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Yulia I UlitinaRIC-Pharma, 123298 Moscow, Russia.
Dmitry I VovkRIC-Pharma, 123298 Moscow, Russia.
Marina V AlikovaRIC-Pharma, 123298 Moscow, Russia.
Anna A KataevaRIC-Pharma, 123298 Moscow, Russia.
Anna V KalenskayaCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.
Irina V SolovjevaCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.
Elena V TivanovaCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.
Larissa Y KondrashevaCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.
Antonina A PloskirevaCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.
Vasiliy G AkimkinCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123 Moscow, Russia.ORCID 0000-0003-4228-9044
Ksenia A SubbotinaPerm State Medical University named after E. A. Wagner of the Ministry of Healthcare of the Russian Federation, 614000 Perm, Russia.
Georgy M IgnatyevChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Anastasia K KordubanChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Elena Y ShustovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Ekaterina O BayurovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0002-6160-2203
Alla S ZhitkevichChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0003-3993-6909
Daria V AvdoshinaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0001-8168-5969
Anastasia N PiniaevaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Anastasia A KovpakChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Liliya P AntonovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Yulia V RogovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Anna A ShishovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0002-5907-0615
Yury Y IvinChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Svetlana E SotskovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Konstantin A ChernovChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Elena G IpatovaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Ekaterina A KordubanChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Aydar A IshmukhametovChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Russian Academy of Sciences · RUCentral Research Institute of Epidemiology · RUFederal Medical-Biological Agency · RUMinistry of Health of the Russian Federation · RUPerm State Medical Academy · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volunteers aged 18-60 and open multi-center comparative phase IIb clinical trial in volunteers aged 60 years and older. The safety of the vaccine was assessed in 400 volunteers in the 18-60 age cohort who received two doses of the vaccine (n = 300) or placebo (n = 100) and in 200 volunteers in 60+ age cohort all of whom received three doses of the vaccine. The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AEs), or other significant AEs related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (

Indexed as

COVID-19COVID-19 VaccinesAgedAntibodies, NeutralizingAntibodies, ViralHumansMiddle AgedVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCOVI-VACVaccines, Attenuated18–60 age cohort60+ age cohortCOVID-19inactivated vaccineneutralizing antibodiesphase I-II clinical trials

Identifiers

PMID37766235
PMCPMC10537914
OpenAlexW4386246424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.